Professional Summary »
Specializing In »
Practice Locations »
Patient Ratings »
Referring Physicians »
Biography
Dr. Lowsky has been an academic clinician and medical researcher in hematopoietic cell transplantation for 20 years and has broad experience and expertise in the field. He has designed, written, implemented and participated in single and multi-center federally-funded clinical trials; and has served on the Stanford IRB and SRC for cancer-oriented clinical trials for over 10 years.
View Full Biography »
Professional Summary
Education & Certifications
- Fellowship: Toronto General Hospital Postgraduate Education (1993) Canada
- Residency: Toronto General Hospital Postgraduate Education (1991) Canada
- Internship: Toronto General Hospital Postgraduate Education (1989) Canada
- Medical Education: McGill University Faculty of Medicine (1988) Canada
- Board Certification: Royal College of Physicians and Surgeons, Hematology (1993)
- Board Certification: Royal College of Physicians and Surgeons, Internal Medicine (1992)
- FRCP, Coll of Physicians/Surgs Canada, Hematology (1993)
- FRCP, Coll of Physicians/Surgs Canada, Internal Medicine (1991)
- MD, McGill University, Medicine (1988)
Administrative Appointments
- Director, Apheresis Unit, Blood and Marrow Transplantation, Stanford University (2005 - Present)
- Director, BMT Fellowship Program, Blood and Marrow Transplantation, Stanford University (2002 - Present)
Publications
-
Approaches to transplantation tolerance in humans
Strober, S., Lowsky, R. J., Shizuru, J. A., Scandling, J. D., & Millan, M. T. (2004). Approaches to transplantation tolerance in humans. TRANSPLANTATION, 77(6), 932–36. -
Short tandem repeat analysis to monitor chimerism in Macaca fascicularis
Lau, M., Vayntrub, T., GRUMET, F. C., Lowsky, R., Strober, S., Hoppe, R., … Borie, D. (2004). Short tandem repeat analysis to monitor chimerism in Macaca fascicularis. AMERICAN JOURNAL OF TRANSPLANTATION, 4(9), 1543–48. -
Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8(+) T-cell dose
Cao, T. M., Shizuru, J. A., Wong, R. M., Sheehan, K., Laport, G. G., Stockerl-Goldstein, K. E., … Lowsky, R. (2005). Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8(+) T-cell dose. BLOOD, 105(6), 2300–2306. -
CD34, CD49 and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies
Cao, T. M., Wong, R. M., Sheehan, K., Laport, G. G., Stockerl-Goldstein, K. E., JOHNSTON, L. J., … Lowsky, R. (2005). CD34, CD49 and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies. EXPERIMENTAL HEMATOLOGY, 33(3), 279–85. -
A technique of bone marrow collection from vertebral bodies of cynomolgus macaques for transplant studies
Flores, M. G., Holm, B., Larson, M. J., Lau, M. K., Si, M. S., Lowsky, R., … Borie, D. C. (2005). A technique of bone marrow collection from vertebral bodies of cynomolgus macaques for transplant studies. JOURNAL OF SURGICAL RESEARCH, 124(2), 280–88. -
Protective conditioning for acute graft-versus-host disease
Lowsky, R., Takahashi, T., Liu, Y. P., Dejbakhsh-Jones, S., GRUMET, F. C., Shizuru, J. A., … Strober, S. (2005). Protective conditioning for acute graft-versus-host disease. NEW ENGLAND JOURNAL OF MEDICINE, 353(13), 1321–31. -
High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma
Law, L. Y., Horning, S. J., Wong, R. M., Johnston, L. J., Laport, G. G., Lowsky, R., … Stockerl-Goldstein, K. E. (2006). High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 12(7), 703–11. -
Tolerance and chimerism after renal and hematopoietic-cell transplantation.
Scandling, J. D., Busque, S., Dejbakhsh-Jones, S., Benike, C., Millan, M. T., Shizuru, J. A., … Strober, S. (2008). Tolerance and chimerism after renal and hematopoietic-cell transplantation. New England Journal of Medicine, 358(4), 362–68. -
TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors
Kohrt, H. E., Turnbull, B. B., Heydari, K., Shizuru, J. A., Laport, G. G., Miklos, D. B., … Lowsky, R. (2009). TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. BLOOD, 114(5), 1099–1109. -
Total lymphoid irradiation for graft-versus-host disease protection.
Kohrt, H., & Lowsky, R. (2009). Total lymphoid irradiation for graft-versus-host disease protection. Current Opinion in Oncology, 21, S23–6. -
Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure
Benjamin, J. E., Chen, G. L., Cao, T. M., Cao, P. D., Wong, R. M., Sheehan, K., … Laport, G. G. (2010). Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure. BONE MARROW TRANSPLANTATION, 45(2), 303–9. -
Nonmyeloablative conditioning with total lymphoid irradiation and antithymocyte globulin: an update
Kohrt, H., & Lowsky, R. (2009). Nonmyeloablative conditioning with total lymphoid irradiation and antithymocyte globulin: an update. CURRENT OPINION IN HEMATOLOGY, 16(6), 460–65. -
Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma
Arai, S., Letsinger, R., Wong, R. M., Johnston, L. J., Laport, G. G., Lowsky, R., … Horning, S. J. (2010). Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 16(8), 1145–54. -
Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY
Naik, S., Wong, R., Arai, S., Brown, J., Laport, G., Lowsky, R., … Johnston, L. (2011). Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY. BONE MARROW TRANSPLANTATION, 46(2), 192–99. -
Complete donor T-cell engraftment 30 days after allogeneic transplantation predicts molecular remission in high-risk chronic lymphocytic leukaemia
Jones, C. D., Arai, S., Lowsky, R., Tyan, D. B., Zehnder, J. L., & Miklos, D. B. (2010). Complete donor T-cell engraftment 30 days after allogeneic transplantation predicts molecular remission in high-risk chronic lymphocytic leukaemia. BRITISH JOURNAL OF HAEMATOLOGY, 150(5), 637–39. -
NKT cells, Treg, and their interactions in bone marrow transplantation
Kohrt, H. E., Pillai, A. B., Lowsky, R., & Strober, S. (2010). NKT cells, Treg, and their interactions in bone marrow transplantation. EUROPEAN JOURNAL OF IMMUNOLOGY, 40(7), 1862–69. -
Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation
Johnston, L., Florek, M., Armstrong, R., McCune, J. S., Arai, S., Brown, J., … Negrin, R. (2012). Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. BONE MARROW TRANSPLANTATION, 47(4), 581–88. -
Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma
Chen, A. I., Negrin, R. S., McMillan, A., Shizuru, J. A., JOHNSTON, L. J., Lowsky, R., … Stockerl-Goldstein, K. (2012). Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma. BONE MARROW TRANSPLANTATION, 47(4), 516–21. -
Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation
Laport, G. G., Sheehan, K., Baker, J., Armstrong, R., Wong, R. M., Lowsky, R., … Negrin, R. S. (2011). Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 17(11), 1679–87. -
Translational studies in hematopoietic cell transplantation: Treatment of hematologic malignancies as a stepping stone to tolerance induction
Strober, S., Spitzer, T. R., Lowsky, R., & Sykes, M. (2011). Translational studies in hematopoietic cell transplantation: Treatment of hematologic malignancies as a stepping stone to tolerance induction. SEMINARS IN IMMUNOLOGY, 23(4), 273–81. -
Donor immunization with WT1 peptide augments antileukemic activity after MHC-matched bone marrow transplantation.
Kohrt, H. E., Müller, A., Baker, J., Goldstein, M. J., Newell, E., Dutt, S., … Strober, S. (2011). Donor immunization with WT1 peptide augments antileukemic activity after MHC-matched bone marrow transplantation. Blood, 118(19), 5319–29. -
Tolerance and Withdrawal of Immunosuppressive Drugs in Patients Given Kidney and Hematopoietic Cell Transplants
Scandling, J. D., Busque, S., Dejbakhsh-Jones, S., Benike, C., Sarwal, M., Millan, M. T., … Strober, S. (2012). Tolerance and Withdrawal of Immunosuppressive Drugs in Patients Given Kidney and Hematopoietic Cell Transplants. AMERICAN JOURNAL OF TRANSPLANTATION, 12(5), 1133–45. -
Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence
Arai, S., Sahaf, B., Narasimhan, B., Chen, G. L., Jones, C. D., Lowsky, R., … Miklos, D. B. (2012). Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. BLOOD, 119(25), 6145–54. -
Rare cells predict GVHD.
Strober, S., & Lowsky, R. (2012). Rare cells predict GVHD. Blood, 119(21), 4820–21. -
Identification of gene microarray expression profiles in patients with chronic graft-versus-host disease following allogeneic hematopoietic cell transplantation.
Kohrt, H. E., Tian, L., Li, L., Alizadeh, A. A., Hsieh, S., Tibshirani, R. J., … Lowsky, R. (2013). Identification of gene microarray expression profiles in patients with chronic graft-versus-host disease following allogeneic hematopoietic cell transplantation. Clinical Immunology , 148(1), 124–35. -
Donor Immunization with WT1 Peptide Augments Anti-Leukemic Activity After MHC-Matched Bone Marrow Transplantation
Kohrt, H. E., Mueller, A. M. S., Baker, J. B., Goldstein, M. J., Newell, E., Dutt, S., … Strober, S. (2011). Donor Immunization with WT1 Peptide Augments Anti-Leukemic Activity After MHC-Matched Bone Marrow Transplantation. BLOOD, 118(21), 827–28. -
Outcomes After Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation with Total Lymphoid Irradiation and Anti-Thymocyte Globulin in Lymphoid Malignancies After Failed Autologous Transplantation
Kanate, A. S., Efron, B., Chhabra, S., Kohrt, H., Shizuru, J. A., Laport, G. G., … Lowsky, R. (2013). Outcomes After Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation with Total Lymphoid Irradiation and Anti-Thymocyte Globulin in Lymphoid Malignancies After Failed Autologous Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 19(2), S154–S155. -
TLI-ATG Conditioning and Allogeneic Transplantation for Patients with MDS and MPN
Benjamin, J., Chhabra, S., Kohrt, H., Laport, G. G., Arai, S., Johnston, L., … Lowsky, R. (2013). TLI-ATG Conditioning and Allogeneic Transplantation for Patients with MDS and MPN. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 19(2), S113–S114. -
Gene Arrays May Predict Stable Clinical Kidney Tolerance and Support Safe Immunosuppression Withdrawal
Sarwal, M. M., Li, L., Hsieh, S.-C., Lowsky, R., Busque, S., Scandling, J., … Strober, S. (2010). Gene Arrays May Predict Stable Clinical Kidney Tolerance and Support Safe Immunosuppression Withdrawal. Presented at the American-Society-of-Transplantation Annual Scientific Exchange, ORLANDO,FL,FL,FL,FL,FL,FL,FL,FL,FL,FL,FL,FL: WILEY-BLACKWELL PUBLISHING, INC. -
Noninvasive Prediction of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation by Gene Expression Profiling.
Li, L., Kohrt, H., Heish, S., Alizadeh, A., Laport, G., Shizuru, J., … Sarwal, M. (2010). Noninvasive Prediction of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation by Gene Expression Profiling. Presented at the 10th American Transplant Congress, SAN DIEGO,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA: WILEY-BLACKWELL. -
Chimerism and Tolerance after Combined Human Kidney and Hematopoietic Cell Transplantation Using Conditioning with Total Lymphoid Irradiation and Anti-Thymocyte Globulin
Lowsky, R., Shizuru, J., Busque, S., Scandling, J., Sarwal, M., Jones, S., … Strober, S. (2008). Chimerism and Tolerance after Combined Human Kidney and Hematopoietic Cell Transplantation Using Conditioning with Total Lymphoid Irradiation and Anti-Thymocyte Globulin. BLOOD, 112(11), 758–58. -
Noninvasive Prediction of Graft-Verus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation by Gene Expression Profiling
Kohrt, H. E., Li, L., Alizadeh, A. A., Goldstein, M. J., Strober, S., Sarwal, M., & Lowsky, R. (2010). Noninvasive Prediction of Graft-Verus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation by Gene Expression Profiling. BLOOD, 116(21), 393–94. -
Gene Arrays May Predict Stable Clinical Tolerance and Support Safe Immunosuppression Withdrawal.
Sarwal, M. M., Li, L., Hsieh, S.-C., Lowsky, R., Busque, S., Scandling, J., … Strober, S. (2009). Gene Arrays May Predict Stable Clinical Tolerance and Support Safe Immunosuppression Withdrawal. Presented at the 9th Joint Meeting of the American-Society-of-Transplant-Surgeon/American-Society-of-Transplantation, BOSTON,MA,MA,MA,MA,MA,MA,MA,MA,MA,MA,MA,MA: WILEY-BLACKWELL. -
Bronchiolitis obliterans organizing pneumonia in a patient with chronic myelogenous leukemia developing after initiation of interferon and cytosine arabinoside
Patel, M., Ezzat, W., Pauw, K. L., & Lowsky, R. (2001). Bronchiolitis obliterans organizing pneumonia in a patient with chronic myelogenous leukemia developing after initiation of interferon and cytosine arabinoside. EUROPEAN JOURNAL OF HAEMATOLOGY, 67(5-6), 318–21. -
Total lymphoid irradiation and transplantation tolerance
Lowsky, R., & Negrin, R. S. (2006). Total lymphoid irradiation and transplantation tolerance. CURRENT OPINION IN ORGAN TRANSPLANTATION, 11(1), 54–61. -
Thymoglobulin and regulatory T cells in organ and hematopoietic cell transplantation
Lowsky, R. (2007). Thymoglobulin and regulatory T cells in organ and hematopoietic cell transplantation. TRANSPLANTATION, 84(11), S20–S26. -
RIZ1 repression is associated with insulin-like growth factor-1 signaling activation in chronic myeloid leukemia cell lines
Pastural, E., Takahashi, N., Dong, W.-F., Bainbridge, M., Hull, A., Pearson, D., … Geyer, C. R. (2007). RIZ1 repression is associated with insulin-like growth factor-1 signaling activation in chronic myeloid leukemia cell lines. ONCOGENE, 26(11), 1586–1594. -
Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms.
Benjamin, J., Chhabra, S., Kohrt, H. E., Lavori, P., Laport, G. G., Arai, S., … Lowsky, R. (2014). Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms. Biology of Blood and Marrow Transplantation , 20(6), 837–43. -
Chimerism, Graft Survival, and Withdrawal of Immunosuppressive Drugs in HLA Matched and Mismatched Patients After Living Donor Kidney and Hematopoietic Cell Transplantation.
Scandling, J. D., Busque, S., Shizuru, J. A., Lowsky, R., Hoppe, R., Dejbakhsh-Jones, S., … Strober, S. (2015). Chimerism, Graft Survival, and Withdrawal of Immunosuppressive Drugs in HLA Matched and Mismatched Patients After Living Donor Kidney and Hematopoietic Cell Transplantation. American Journal of Transplantation , 15(3), 695–704. -
Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile.
Percival, M.-E. M., Medeiros, B. C., Tian, L., Robeson, S., Laport, G. G., Johnston, L. J., … Lowsky, R. (2015). Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile. Bone Marrow Transplantation. -
Risks and benefits of sex-mismatched hematopoietic cell transplantation differ according to conditioning strategy.
Nakasone, H., Remberger, M., Tian, L., Brodin, P., Sahaf, B., Wu, F., … Meyer, E. (2015). Risks and benefits of sex-mismatched hematopoietic cell transplantation differ according to conditioning strategy. Haematologica, 100(11), 1477–85. -
Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning
Rezvani, A. R., Kanate, A. S., Efron, B., Chhabra, S., Kohrt, H. E., Shizuru, J. A., … Lowsky, R. (2015). Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning. BONE MARROW TRANSPLANTATION, 50(10), 1286–92. -
Brief report: Tolerance and chimerism after renal and hematopoietic-cell transplantation
Scandling, J. D., Busque, S., Dejbakhsh-Jones, S., Benike, C., Millan, M. T., Shizuru, J. A., … Strober, S. (2008). Brief report: Tolerance and chimerism after renal and hematopoietic-cell transplantation. NEW ENGLAND JOURNAL OF MEDICINE, 358(4), 362–68. -
Donor immunization with WT1 peptide augments antileukemic activity after MHC-matched bone marrow transplantation
Kohrt, H. E., Mueller, A., Baker, J., Goldstein, M. J., Newell, E., Dutt, S., … Strober, S. (2011). Donor immunization with WT1 peptide augments antileukemic activity after MHC-matched bone marrow transplantation. BLOOD, 118(19), 5319–29. -
The Blood and Marrow Transplant Clinical Trials Network: An Effective Infrastructure for Addressing Important Issues in Hematopoietic Cell Transplantation
Alousi, A. M., Anasetti, C., Antin, J. H., Appelbaum, F. R., Bashey, A., Confer, D. L., … Yanik, G. A. (2016). The Blood and Marrow Transplant Clinical Trials Network: An Effective Infrastructure for Addressing Important Issues in Hematopoietic Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 22(10), 1747–1757. -
Pregnancy Complicated by Gorham-Stout Disease and Refractory Chylothorax.
Hellyer, J., Oliver-Allen, H., Shafiq, M., Tolani, A., Druzin, M., Jeng, M., … Lowsky, R. (2016). Pregnancy Complicated by Gorham-Stout Disease and Refractory Chylothorax. AJP Reports, 6(4), e355–e358. -
PD-1 blockade for relapsed lymphoma post allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.
Haverkos, B. M., Abbott, D., Hamadani, M., Armand, P., Flowers, M. E., Merryman, R., … Devine, S. M. (2017). PD-1 blockade for relapsed lymphoma post allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood. -
HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity.
Spinner, M. A., Fernández-Viña, M., Creary, L. E., Quinn, O., Elder, L., Arai, S., … Rezvani, A. R. (2017). HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity. Blood Advances, 1(17), 1347–57. -
Macrochimerism and clinical transplant tolerance.
Scandling, J. D., Busque, S., Lowsky, R., Shizuru, J., Shori, A., Engleman, E., … Strober, S. (2018). Macrochimerism and clinical transplant tolerance. Human Immunology. -
Long-Term Outcomes of AML Patients Using Total Lymphoid Irradiation with Anti-Thymocyte Globulin
Nakasone, H., Miklos, D. B., Meyer, E., Rezvani, A., Muffly, L., Weng, W.-K., … Lowsky, R. (2016). Long-Term Outcomes of AML Patients Using Total Lymphoid Irradiation with Anti-Thymocyte Globulin. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. ELSEVIER SCIENCE INC. -
Donor-Derived CIK Cell Infusion As Consolidative Therapy after Non-Myeloablative Allogeneic Transplant in Patients with Myeloid Neoplasms
Narayan, R., Benjamin, J., Laport, G., Tian, L., Tate, K., Elder, L., … Meyer, E. (2015). Donor-Derived CIK Cell Infusion As Consolidative Therapy after Non-Myeloablative Allogeneic Transplant in Patients with Myeloid Neoplasms. BLOOD. AMER SOC HEMATOLOGY. -
Infusion of donor-derived CD8(+) memory T cells for relapse following allogeneic hematopoietic cell transplantation
Muffly, L., Sheehan, K., Armstrong, R., Jensen, K., Tate, K., Rezvani, A. R., … Lowsky, R. (2018). Infusion of donor-derived CD8(+) memory T cells for relapse following allogeneic hematopoietic cell transplantation. BLOOD ADVANCES, 2(6), 681–90. -
Phase I/II Trial for Patients with Advanced Hematologic Malignancies Undergoing Myeloablative Allogeneic HCT with a T Cell Depleted Graft with Infusion of Conventional T Cells and Regulatory T Cells
Meyer, E., Laport, G. G., Tantsura, I., Tang, S. W., Sahaf, B., Rangarajan, K., … Negrin, R. S. (2018). Phase I/II Trial for Patients with Advanced Hematologic Malignancies Undergoing Myeloablative Allogeneic HCT with a T Cell Depleted Graft with Infusion of Conventional T Cells and Regulatory T Cells. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 24(3), S145. -
Phase I/II study of intratumoral injection of SD-101, an immunostimulatory CpG, and intratumoral injection of ipillumumab, an anti-CTLA-4 monoclonal antibody, in combination with local radiation in low-grade B-cell lymphomas.
Khodadoust, M. S., Chu, M. P., Czerwinski, D., McDonald, K., Long, S., Kohrt, H. E., … Levy, R. (2015). Phase I/II study of intratumoral injection of SD-101, an immunostimulatory CpG, and intratumoral injection of ipillumumab, an anti-CTLA-4 monoclonal antibody, in combination with local radiation in low-grade B-cell lymphomas. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Identification of Candidate Transcriptional Biomarkers Associated with Chronic Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation
Kohrt, H. E., Tian, L., Li, L., Alizadeh, A. A., Hsieh, S., Strober, S., … Lowsky, R. (2012). Identification of Candidate Transcriptional Biomarkers Associated with Chronic Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation. BLOOD, 120(21). -
Non-Myeloablative Allogeneic Transplantation Resulting in Clinical and Molecular Remission with Low Non-Relapse Mortality (NRM) in Patients with Advanced Stage Mycosis Fungoides (MF) and Sezary Syndrome (SS)
Weng, W.-K., Armstrong, R., Arai, S., Johnston, L., Laport, G. G., Lowsky, R., … Kim, Y. H. (2014). Non-Myeloablative Allogeneic Transplantation Resulting in Clinical and Molecular Remission with Low Non-Relapse Mortality (NRM) in Patients with Advanced Stage Mycosis Fungoides (MF) and Sezary Syndrome (SS). BLOOD, 124(21). -
Outcome of Tandem Autologous/Allogeneic Hematopoietic Cell Transplantation in High-Risk Non Hodgkin's Lymphoma Patients: Stanford University Experience
Wudhikarn, K., Lavori, P., Arai, S., Johnston, L., Laport, G. G., Lowsky, R., … Weng, W.-K. (2014). Outcome of Tandem Autologous/Allogeneic Hematopoietic Cell Transplantation in High-Risk Non Hodgkin's Lymphoma Patients: Stanford University Experience. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. ELSEVIER SCIENCE INC. -
Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation
Veeraputhiran, M., Yang, L., Sundaram, V., Arai, S., Lowsky, R., Miklos, D., … Johnston, L. (2017). Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 23(10), 1744–48. -
Immune Characterization of Ibrutinib Therapy Following Allohct That Provides GVL Benefit without Gvhd
Sahaf, B., Ryan, C. E., Rezvani, A., Nakasone, H., Otani, J., Coutre, S., … Miklos, D. B. (2016). Immune Characterization of Ibrutinib Therapy Following Allohct That Provides GVL Benefit without Gvhd. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 22(3), S412. -
Risks and Benefits of Sex-Mismatched Hematopoietic Cell Transplantation Differ By Conditioning Intensity
Nakasone, H., Remberger, M., Tian, L., Brodin, P., Sahaf, B., Wu, F., … Meyer, E. (2014). Risks and Benefits of Sex-Mismatched Hematopoietic Cell Transplantation Differ By Conditioning Intensity. BLOOD. AMER SOC HEMATOLOGY. -
Risks and Benefits of Sex-Mismatched Hematopoietic Cell Transplantation Differ By Conditioning Strategy
Nakasone, H., Remberger, M., Tian, L., Brodin, P., Sahaf, B., Wu, F., … Meyer, E. (2015). Risks and Benefits of Sex-Mismatched Hematopoietic Cell Transplantation Differ By Conditioning Strategy. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. ELSEVIER SCIENCE INC. -
Allogeneic transplantation using TLI-ATG conditioning for Hodgkin lymphoma after failure of autologous transplantation.
Spinner, M. A., Advani, R. H., Hoppe, R. T., Lowsky, R., & Muffly, L. S. (2018). Allogeneic transplantation using TLI-ATG conditioning for Hodgkin lymphoma after failure of autologous transplantation. Blood Advances, 2(13), 1547–50. -
Immunosuppressive myeloid cells in patients given combined kidney and hematopoietic cell transplants in a tolerance protocol with TLI and ATG conditioning
Jensen, K., Scandling, J., Busque, S., Shizuru, J., Lowsky, R., Saraswathula, A., … Strober, S. (2016). Immunosuppressive myeloid cells in patients given combined kidney and hematopoietic cell transplants in a tolerance protocol with TLI and ATG conditioning. TRANSPLANTATION, 100(7), S5. -
Relationship between mixed chimerism and clinical tolerance after combined kidney and hematopoietic cell transplantation using total lymphoid irradiation and antithymocyte globulin conditioning
Busque, S., Scandling, J. D., Shizuru, J., Lowsky, R., Shori, A., Jensen, K., … Strober, S. (2016). Relationship between mixed chimerism and clinical tolerance after combined kidney and hematopoietic cell transplantation using total lymphoid irradiation and antithymocyte globulin conditioning. TRANSPLANTATION, 100(7), S245. -
Allogeneic Transplants from HLA-Mismatched Unrelated Donors Using Total Lymphoid Irradiation and Antithymocyte Globulin Conditioning Retain a Low Risk of Graft-Versus-Host Disease and Non-Relapse Mortality with at Least As Potent Anti-Tumor Activity As with Matched Unrelated Donors
Spinner, M. A., Vina, M. F., Elder, L., Arai, S., Johnston, L., Meyer, E., … Rezvani, A. R. (2016). Allogeneic Transplants from HLA-Mismatched Unrelated Donors Using Total Lymphoid Irradiation and Antithymocyte Globulin Conditioning Retain a Low Risk of Graft-Versus-Host Disease and Non-Relapse Mortality with at Least As Potent Anti-Tumor Activity As with Matched Unrelated Donors. BLOOD. AMER SOC HEMATOLOGY. -
Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematologic Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation
Muffly, L. S., Sheehan, K., Armstrong, R., Tate, K., Tudisco, C., Rezvani, A. R., … Lowsky, R. (2016). Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematologic Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation. BLOOD. AMER SOC HEMATOLOGY. -
Relationship Between Mixed Chimerism and Acceptance of HLA-matched and -Mismatched Kidney Transplants after Withdrawal of Immunosuppressive Drugs
Busque, S., Scandling, J., Lowsky, R., Shizuru, J., Jensen, K., Shori, A., … Strober, S. (2018). Relationship Between Mixed Chimerism and Acceptance of HLA-matched and -Mismatched Kidney Transplants after Withdrawal of Immunosuppressive Drugs. TRANSPLANTATION, 102, S393. -
AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION FOR TREATMENT-REFRACTORY RELAPSING MULTIPLE SCLEROSIS: POSITION STATEMENT FROM THE AMERICAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION.
Cohen, J. A., Baldassari, L. E., Atkins, H. L., Bowen, J. D., Bredeson, C., Carpenter, P. A., … Georges, G. E. (2019). AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION FOR TREATMENT-REFRACTORY RELAPSING MULTIPLE SCLEROSIS: POSITION STATEMENT FROM THE AMERICAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation. -
Nonmyeloablative Allogeneic Transplantation Using TLI-ATG Conditioning for Lymphoid and Myeloid Malignancies: Mature Follow-up from a Large, Single Institution Cohort
Spinner, M. A., Kennedy, V. E., Tamaresis, J. S., Lavori, P. W., Elder, L. V., Arai, S., … Lowsky, R. (2018). Nonmyeloablative Allogeneic Transplantation Using TLI-ATG Conditioning for Lymphoid and Myeloid Malignancies: Mature Follow-up from a Large, Single Institution Cohort. BLOOD, 132. -
Elevated Axicabtagene Ciloleucel (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma
Spiegel, J. Y., Sahaf, B., Hossain, N., Frank, M. J., Claire, G., Abramian, M., … Miklos, D. B. (2018). Elevated Axicabtagene Ciloleucel (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma. BLOOD. AMER SOC HEMATOLOGY. -
Donor-derived CIK Cell Infusion as Consolidation after Non-myeloablative Allogeneic Transplant for Myeloid Neoplasms.
Narayan, R., Benjamin, J. E., Shah, O., Tian, L., Tate, K., Armstrong, R., … Meyer, E. H. (2019). Donor-derived CIK Cell Infusion as Consolidation after Non-myeloablative Allogeneic Transplant for Myeloid Neoplasms. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation. -
Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients.
Meyer, E. H., Laport, G., Xie, B. J., MacDonald, K., Heydari, K., Sahaf, B., … Negrin, R. S. (2019). Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients. JCI Insight, 4(10). -
Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients
Meyer, E. H., Laport, G., Xie, B. J., MacDonald, K., Heydari, K., Sahaf, B., … Negrin, R. S. (2019). Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients. JCI INSIGHT, 4(10). -
Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation
Cohen, J. A., Baldassari, L. E., Atkins, H. L., Bowen, J. D., Bredeson, C., Carpenter, P. A., … Georges, G. E. (2019). Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 25(5), 845–54. -
Donor-Derived Cytokine-Induced Killer Cell Infusion as Consolidation after Nonmyeloablative Allogeneic Transplantation for Myeloid Neoplasms
Narayan, R., Benjamin, J. E., Shah, O., Tian, L., Tate, K., Armstrong, R., … Meyer, E. H. (2019). Donor-Derived Cytokine-Induced Killer Cell Infusion as Consolidation after Nonmyeloablative Allogeneic Transplantation for Myeloid Neoplasms. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 25(7), 1293–1303. -
Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort.
Spinner, M. A., Kennedy, V. E., Tamaresis, J. S., Lavori, P. W., Arai, S., Johnston, L. J., … Lowsky, R. (2019). Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort. Blood Advances, 3(16), 2454–64. -
Assessment by Extended-Coverage Next-Generation Sequencing Typing of DPA1 and DPB1 Mismatches in Siblings Matching at HLA-A, -B, -C, -DRB1, and -DQ Loci.
Mariano, L., Zhang, B. M., Osoegawa, K., Lowsky, R., & Fernandez-Vina, M. (2019). Assessment by Extended-Coverage Next-Generation Sequencing Typing of DPA1 and DPB1 Mismatches in Siblings Matching at HLA-A, -B, -C, -DRB1, and -DQ Loci. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation. -
Combined kidney and hematopoeitic cell transplantation to induce mixed chimerism and tolerance.
Lowsky, R., & Strober, S. (2019). Combined kidney and hematopoeitic cell transplantation to induce mixed chimerism and tolerance. Bone Marrow Transplantation, 54(Suppl 2), 793–97. -
Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma: Long-term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial.
Giralt, S., Costa, L. J., Maloney, D., Krishnan, A., Fei, M., Antin, J. H., … Stadtmauer, E. (2019). Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma: Long-term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation. -
Mixed chimerism and acceptance of kidney transplants after immunosuppressive drug withdrawal.
Busque, S., Scandling, J. D., Lowsky, R., Shizuru, J., Jensen, K., Waters, J., … Strober, S. (2020). Mixed chimerism and acceptance of kidney transplants after immunosuppressive drug withdrawal. Science Translational Medicine, 12(528). -
Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia: Significant Increase in Survival in the Post-Targeted Immunotherapy Era
Muffly, L., Arai, S., Johnston, L., Lowsky, R., Meyer, E. H., Miklos, D. B., … Cunanan, K. (2020). Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia: Significant Increase in Survival in the Post-Targeted Immunotherapy Era. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 26(3), S106. -
Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma.
Lemieux, C., Muffly, L. S., Rezvani, A., Lowsky, R., Iberri, D. J., Craig, J. K., … Sidana, S. (2020). Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma. Bone Marrow Transplantation. -
Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma.
Weng, W.-K. K., Arai, S., Rezvani, A., Johnston, L., Lowsky, R., Miklos, D., … Kim, Y. H. (2020). Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma. Blood Advances, 4(18), 4474–82. -
Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents.
Lemieux, C., Johnston, L. J., Lowsky, R., Muffly, L. S., Craig, J. K., Shiraz, P., … Sidana, S. (2020). Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation. -
CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma.
Baird, J. H., Frank, M. J., Craig, J., Patel, S., Spiegel, J. Y., Sahaf, B., … Muffly, L. (2020). CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma. Blood. -
Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma
Baird, J. H., Epstein, D. J., Tamaresis, J. S., Ehlinger, Z., Spiegel, J. Y., Craig, J., … Sidana, S. (2021). Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma. BLOOD ADVANCES, 5(1), 143–55. -
Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma.
Baird, J. H., Epstein, D. J., Tamaresis, J. S., Ehlinger, Z., Spiegel, J. Y., Craig, J., … Sidana, S. (2021). Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma. Blood Advances, 5(1), 143–155. -
Autologous stem cell transplantation versus no transplant in patients above 70 with multiple myeloma.
Lemieux, C., Muffly, L. S., Iberri, D. J., Rezvani, A., Lowsky, R., Frank, M. J., … Sidana, S. (2020). Autologous stem cell transplantation versus no transplant in patients above 70 with multiple myeloma. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Impact of proteasome inhibitor vs. IMiD maintenance therapy on outcomes of patients with high-risk multiple myeloma (HRMM).
Tam, E. L., Iberri, D. J., Liedtke, M., Muffly, L. S., Shiraz, P., Frank, M. J., … Sidana, S. (2020). Impact of proteasome inhibitor vs. IMiD maintenance therapy on outcomes of patients with high-risk multiple myeloma (HRMM). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma.
Merryman, R. W., Castagna, L., Giordano, L., Ho, V. T., Corradini, P., Guidetti, A., … Carlo-Stella, C. (2021). Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia. -
Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.
Liang, E. C., Muffly, L. S., Shiraz, P., Shizuru, J. A., Johnston, L., Arai, S., … Sidana, S. (2021). Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Transplantation and Cellular Therapy. -
Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor vs. G-CSF +/- Plerixafor in the Lenalidomide Era.
Johnsrud, A., Ladha, A., Muffly, L., Shiraz, P., Goldstein, G., Osgood, V., … Sidana, S. (2021). Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor vs. G-CSF +/- Plerixafor in the Lenalidomide Era. Transplantation and Cellular Therapy. -
Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma.
Lemieux, C., Muffly, L. S., Iberri, D. J., Craig, J. K., Johnston, L. J., Lowsky, R., … Sidana, S. (2021). Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma. Bone Marrow Transplantation. -
Inferior Clinical Outcomes in Recipients of Cryopreserved Grafts Following Reduced Intensity Allogeneic Hematopoietic Cell Transplantation: A Single Center Report
Bankova, A., Caveney, J., Ramos, T., Bogeholz, J., Heydari, K., Diaz, N., … Arai, S. (2021). Inferior Clinical Outcomes in Recipients of Cryopreserved Grafts Following Reduced Intensity Allogeneic Hematopoietic Cell Transplantation: A Single Center Report. BONE MARROW TRANSPLANTATION. SPRINGERNATURE. -
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.
Spiegel, J. Y., Patel, S., Muffly, L., Hossain, N. M., Oak, J., Baird, J. H., … Miklos, D. B. (2021). CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nature Medicine. -
Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia.
Muffly, L., Sundaram, V., Chen, C., Yurkiewicz, I., Kuo, E., Burnash, S., … Miklos, D. B. (2021). Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia. Blood Advances, 5(16), 3147–3151. -
Development of immunosuppressive myeloid cells to induce tolerance in solid organ and hematopoietic cell transplant recipients.
Jensen, K. P., Hongo, D., Ji, X., Zheng, P., Pawar, R. D., Wu, H.-H., … Strober, S. (2021). Development of immunosuppressive myeloid cells to induce tolerance in solid organ and hematopoietic cell transplant recipients. Blood Advances. -
Incidence and Risk Factors Associated with Bleeding and Thrombosis Following Chimeric Antigen Receptor T Cell Therapy.
Johnsrud, A. J., Craig, J., Baird, J. H., Spiegel, J. Y., Muffly, L., Zehnder, J. L., … Sidana, S. (2021). Incidence and Risk Factors Associated with Bleeding and Thrombosis Following Chimeric Antigen Receptor T Cell Therapy. Blood Advances.
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant »
- Inducing Graft Tolerance in HLA Haplotype Matched Related and 3 Ag Matched Unrelated Living Donor Kidney Transplantation »
- MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC »
- Bone Marrow Grafting for Leukemia and Lymphoma »
- Combined Blood Stem Cell and Kidney Transplant of One Haplotype Match Living Donor Pairs. »
- CIBMTR Research Database »
- Perinatal Arterial Stroke: A Multi-site RCT of Intensive Infant Rehabilitation (I-ACQUIRE) »
- Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies »
- Allo BMT in Advanced Leukemia or High Grade Lymphoma »
- Acute Graft-versus-Host Disease Treatment (BMT CTN 0802) »
- Targeted Therapy of Bronchiolitis Obliterans Syndrome »
- TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD »
- Transplantation for Patients With Chronic Lymphocytic Leukemia »
- Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies »
Practice Locations
Blood and Marrow Transplant Program (BMT) - 900 Blake Wilbur Drive Palo Alto, CA
Palo Alto, CA
Blood and Marrow Transplant Program (BMT) - 900 Blake Wilbur Drive
900 Blake Wilbur Drive, 2nd Floor
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Important Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(108 reviews)
He’s the best
Dr Lowsky and his team are very professional and welcoming.
Dr Lowsky is such a great dr. He always made me feel very comfortable. He was kind, compassionate and had a great sense of humor. I always felt safe and very positive when speaking to him.
Very organized team
He is the very best in his field!!!!
He talks to you like a peer without dumbing anything down. I am beyond honored to even know him.
Very good doctor, more doctors should care about their patients as he does.
Dr Lowsky is a great doctor for all these reasons and more - intelligence, compassion, honesty and a sense of humor.
Dr. Lowsky is very professional and knowledgeable. But he is also very friendly and caring. He has what they used to call a good "bedside manner". He is an excellent doctor and Stanford is lucky to have him.
Dr. Lowsky expalined the procedure in a very meaningful way. He was extremely personable and easy to talk with. Thank you, Dr. Lowsky.
I feel very comfortable being in the care of Dr Lowsky. He is a very competent doctor.
He is an excellent Doctor whom I am thankful to have providing my care.
As always, a pleasure to meeting with you and draw upon your knowledge.
Dr. Lowsky is wonderful to work with. Feel blessed to be in his care.
Very pleased with care and treatment, as well as general demeanor and pleasant conversation
Excellent Consultation. Good Communication.
Doctor Lowsky is fantastic! I don't feel I could have been any luckier if I had $1,000,000 to spend on my healthcare he makes me feel well taking care of his observant he Notices things And then will proceed to ask questions about them. You makes me feel very comfortable . I would say that my care with Stanford and doctor Low sky Has been superior !
He is an excellent doctor who can listen well and response well.
He’s an excellent doctor. Excellent communication skills and excellent explanations.
He was very clear and concise. He spoke at a good pace and answered all my questions
Excellent Dr
He will be my Hero for as long as I live and that includes Sandy too!
Dr Lowsky has been honest about this whole experience. We always knew what to expect. Good or bad. He is the best Doctor we could have hoped for.
Very kind expressive of sympathy and hope
Dr. Lowsky was professional, compassionate and brilliant. I could not have asked for more.
I very much appreciate how Dr. Lowsky treats me as a whole person and not just the disease. He makes a point to ask about social, and psychological issues and he always remembers my dog's name which is very sweet.
On our first visit, he said (having this disease) is not my fault. I burst into tears, not realizing I was holding so much guilt. What a gift of compassion and understanding.
He also seems comfortable enough to give difficult news such as life expectancy.
I also appreciate how he does not seem rushed with me. He is so very kind.
I feel very grateful he's my doctor.
Thank you for being an amazing and uplifting Doctor. You and your team were top notch.
Dr. Lowsky is an amazing doctor. I am eternally grateful to have someone like him still taking care of me 11 years after the transplant. There is nothing I can say that can do justice to how much I respect and admire Dr. Lowsky not just professionally but also from a personal point of view.
Stanford is extraordinarily lucky to have Dr. Lowsky.
I thought he was very informative and thorough.
I was extremely please with the overall visit.
He is a caring Doctor. Always forward and straight to the point.
Very clean.
I can’t say enough good things about the care I have been provided by Dr Lowsky- and Sandy
He's very kind and empathetic and clear in his explanations. Very grateful for him.
Made me feel very comfortable and he genuinely appeared sincere. I’ve had a few nurses and Doctors that it almost appeared they were just doing a job, no compassion.
Dr. Lowsky, was a very informative Doctor. He show since of the patient concern.
I felt relieved after our visit
Very thorough, personal, and comprehensive.
Truly appreciate your ongoing clarity, frankness, and support.
Already have recommended Stanford Md to others
Great doctor love him he's the best
Dr Lowsky is the best.
I hold Robert Lowskey in the highest regard, I trust him with my life.
Dr.Lowsky is the Best Doctor!!
There is no words to describe how grateful we are for his love and devotion to his patients!
He is just amazing at what he dose !!
Thank you Dr. Lowsky !
God bless you .
Merry Christmas and Happy New year !!
From me and my wife!
Extremely well informed about my medical condition, clear about future plans, and generally supportive yet realistic regarding possible complications.
Dr. Lowsky is without any doubt one of the best doctors I have had and unfortunately, I have had quite a few. He is very accomplished, explains issues very clearly and I can always rely on him for the best medical advice and guidance. I have blind faith in Dr. Lowsky and Stanford is lucky to have a jewel like him in their BMT staff.
I'm blessed to have Robert Lowsky as my BMT doctor.
Dr. Lowsky is very caring and tries to provide the best help for his patients.
Really took their time with me, not rushed. Asked after my wellbeing.
Dr. Lowsky was very thorough in his explanations. He made me feel confident that all my health needs were being met.
Stanford is excellent - wow!
Dr. Lowsky was direct and clear in his explanations and took the time to listen to me and answer all my questions.
Dr. Lowsky is an outstanding doctor. A+++. I am grateful Dr. Lowsky is my doctor at Stanford. Simply outstanding, caring, understanding doctor.
Very patient and took all the time to answer my questions. Very motivating and was able to explain the process very well.
Dr. Lowsky is the best. I would not have done the transplant if it were not for him. His warmth, concern & HONESTY did it for me.
I can't say enough good things about Dr. Lowsky. He explains every thing well, went back through my history and told me at what point I will need treatment, treatment options etc. I always leave his office feeling like I am well cared for and don't worry so much about my health. I would travel to see Dr. Lowsky wherever he practiced.
Above & beyond!
All the staff here are great.
I have the best care provider!
Dr. Lowsky is a wonderful doctor one of the best I have ever met with. Perhaps the best doctors appointment I have ever had. He is amazing.
Excellent service from health provider.
Dr. Lowsky was a wonderful teacher, & we all felt very relieved by his expertise & ability to impart information.
Dr. Lowsky and Ms, Romani (RN) were very clear with informing me of my proposed treatment.
GREAT DOCTOR!
Best!
Both nurse Sandra Burgess and Dr. R. Lowsky spent time with me to listen as well as inform and explain to me about my test results, etc.
All excellent.
He is the best.
Cannot say enough about Dr. Lowsky and his team - Dr. Lowsky is beyond anyone we've seen.
The doctor's treatment towards me was excellent!
Outstanding!
Your care provider is at the top went it come to friendliness, courtesy.
Dr. Lowsky is always a positive and encouraging doctor. He really cares about all his patients.
Dr. Lowsky should be cloned he is outstanding and always available to his patients.
They took the time to explain with details all my questions. I left feeling in a good mood.
My dr is the best.
Dr. Lowsky is always very patient and helpful.
Dr. Lowsky is very detailed and knowledgeable. I easily became confident on him.
Dr. Robert Lowsky is the best physician I have ever consulted. I simply can not overstate how knowledgeable, patient, kind, and caring he is. THE BEST.
Dr. Lowsky provided information with friendliness and compassion. His explanations were completed in the modes of learning.
Dr. Lowsky was one of the best physicians I've seen.
Dr. Lowsky has been an exceptionally compassionate doctor for me. I was anxious this visit because of recent lab results. Dr. Lowsky, gave me excellent reassurances with due respect to my particular (I research my case a lot withmedical studies) and sensitivity to my emotional and psychological state.
(Dr.) GREAT - (ASSISTANT) - Sometimes we had to call back.
Dr.'s and nurses answered questions thoroughly and made a comfortable environment.
Dr. Lowsky & staff are the best.
Dr. Lowsky is a superb doctor - professional - caring - concerned - talented - knows his field.
Great explanation of options, transplant time lines, and outcomes.
Dr. Lowsky is a great doctor and person!
It's a great hospital always make me feel good.
Dr. Lowsky is always great (5) in all of these areas.
Good.
Dr. Lowsky is really an excellent doctor and very thorough & compassionate. He is the BEST.
Love Dr. Lowsky. Always explains things to me that I can understand. I know he cares about me and my disease.
My provider never seems rushed and I feel that he has a genuine concern for my well being.
Dr. Lowsky is an excellent physician and care provider.
The doctor was wonderful! He answered all my questions & even drew me a diagram.
Excellent communication skills.
Very good in explaining everything that would take place if needed.
Caring, trustworthy, interested in all of me - mind/body/spirit we feel, 100% that Dr. Lowsky has been one of our best dr.'s! He deserves a raise & recognition for the care of his patients.
Dr. Lowsky is the BEST! Can't say enough good about him. WONDERFUL.
Dr. Lowsky was the easiest to understand. It was important to him I understood.
Dr. Lowsky is the best of the best!
Awesome results.
PA was quiet & didn't seem friendly yet the Dr. Lowsky was excellent.
I LOVE Dr. Lowsky. He explains everything to me & writes it down so I remember. I can email him & get an answer quickly.
Very good.
Very warm - seems to be genuinely concerned. Never felt rushed.
Dr. Lowsky takes a great interest in his patients and he definitely tries to see his patients ASAP.
View More »
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referring Physicians.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- View referral status
- Access medical records